Switzerland’s Federal Office of Public Health recommended Nuvaxovid (NVX-CoV2373) as a heterologous and homologous booster for immunization to prevent COVID -19 caused by severe acute respiratory syndrome
Novavax annnounced that Switzerland’s Federal Office of Public Health (FOPH) has recommended Nuvaxovid(NVX-CoV2373) as a heterologous and homologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 in adults aged 18 and older
The FOPH now recommends use of Nuvaxovid as an adult booster regardless of previous vaccine history as part of its autumn 2022 COVID-19 vaccine booster campaign.
-Novavax annnounced that Switzerland’s Federal Office of Public Health (FOPH) has recommended Nuvaxovid(NVX-CoV2373) as a heterologous and homologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 in adults aged 18 and older. The FOPH now recommends use of Nuvaxovid as an adult booster regardless of previous vaccine history as part of its autumn 2022 COVID-19 vaccine booster campaign.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins